Evidence map›Paper›PMID 39117932›Full record

ArticleEuropean journal of human genetics : EJHG2024

Late-onset tumors in rhabdoid tumor predisposition syndrome type-1 (RTPS1) and implications for surveillance.

Yoshiko Nakano, Meryl Acker, Harriet Druker, Kalene van Engelen, M Stephen Meyn, Jonathan D Wasserman, Rosemarie E Venier, Catherine Goudie, Ana Stosic, Annie Huang and 4 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Looking back at 2024 in the European Journal of Human Genetics.European journal of human genetics : EJHG · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yoshiko Nakano *Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0001-5394-8194
Meryl Acker *Genetics and Genome Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Harriet DrukerDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Kalene van EngelenMedical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, ON, Canada.
M Stephen MeynCenter for Human Genomics and Precision Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Jonathan D WassermanDepartment of Pediatrics, University of Toronto, Toronto, ON, Canada.
Rosemarie E VenierGenetics and Genome Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.ORCID 0000-0001-6063-7562
Catherine GoudieDepartment of Pediatrics, McGill University Health Centre, Montreal, QC, Canada.
Ana StosicGenetics and Genome Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Annie HuangDivision of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Mary-Louise C GreerDepartment of Diagnostic and Interventional Radiology, The Hospital for Sick Children, Department of Medical Imaging, University of Toronto, Toronto, ON, Canada.
David MalkinDivision of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0001-5752-9763
Anita VillaniDivision of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada. anita.villani@sickkids.ca.ORCID 0000-0003-3283-2197
Bailey GallingerGenetics and Genome Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.ORCID 0000-0003-0039-3652

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhabdoid tumor predisposition syndrome type-1 (RTPS1) is characterized by germline pathogenic variants in SMARCB1 and development of INI1-deficient rhabdoid tumors in early childhood. Due to its poor prognosis, the risk of subsequent tumor development and the impact of surveillance at later ages are poorly understood. We retrospectively reviewed individuals referred to the Cancer Genetics Program at The Hospital for Sick Children for SMARCB1 genetic testing and/or surveillance for RTPS1. In addition, to explore characteristics of late-onset tumors in RTPS1, a literature review was conducted. Of eighty-three individuals (55 probands and 28 family members), 12 probands and 4 family members were genetically confirmed with RTPS1. Four pediatric probands with RTPS1 underwent surveillance. An additional three individuals, including one patient with 22q11.2 distal deletion without history of tumor, one patient with negative genetic testing results but clinically diagnosed with RTPS1, and one sibling identified through cascade testing, underwent surveillance. Three patients with RTPS1 developed tumors between the ages of 9 and 17, including malignant rhabdoid tumors (N = 3), schwannomas (N = 4), and epithelioid malignant peripheral nerve sheath tumor (N = 1). Three of these lesions were asymptomatically detected by surveillance. A literature review revealed 17 individuals with RTPS1 who developed INI1-deficient tumors after age five. Individuals with RTPS1 remain at elevated risk for developing INI1-deficient tumors after the peak age of rhabdoid tumor in early childhood. Extension of surveillance beyond 5 years of age could lead to improved survival and reduced morbidity for these patients, and prospective evaluation of revised approaches will be important.

Indexed as

Rhabdoid TumorSMARCB1 ProteinAdolescentAdultAge of OnsetBrain NeoplasmsChildChild, PreschoolFemaleGenetic TestingHumansInfantKidney NeoplasmsMaleNeoplastic Syndromes, HereditarySMARCB1 ProteinSMARCB1 protein, human

Identifiers

PMID39117932
PMCPMC11576963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.